Aktis Oncology, Inc. (AKTS) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−13.8x

Market Cap

$1.50B

MomentumView details →

1D Return

+0.97%

YTD Return

—

RSI (14)

61.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−13.8x

Market Cap

$1.50B

RSI (14)

61.0

MomentumView details →

1D Return

+0.97%

YTD Return

—

ProfitabilityView details →

Gross Margin

83.74%

Net Margin

−739.99%

EBITDA Margin

−762.17%

ROE (TTM)

−14.37%

ROA (TTM)

−12.49%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+336.92%

EPS CAGR 3Y

+5.56%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$0.44

EPS Surprise

−2.17%

Beats (12Q)

0/12

Next Q EPS Est

−$0.44

Avg Surprise (4Q)

−2.17%

Rev Surprise

25.44%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

16.33x

Quick Ratio

16.33x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

9.41M

Net Income (TTM)

−69.66M

Op. CF (TTM)

−72.87M

Next earningsNov 12, 2026 →

Latest newsMore news →

Aktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.23d ago

Similar companies

Absci CorporationABSI Ultragenyx Pharmaceutical Inc.RARE Vor Biopharma Inc.VOR Bicara Therapeutics Inc. Common StockBCAX ArriVent BioPharma, Inc. Common StockAVBP Innoviva, Inc.INVA Find similar companies →

Latest newsMore news →

Aktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.23d ago